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High recurrence rate is one representative characteristic of bladder cancer. Intravesical therapy after transurethral resection is
often performed in patients with nonmuscle invasive bladder cancer (NMIBC) to prevent recurrence. Bacillus Calmette-Guérin
(BCG) and several anticancer/antibiotic agents, such as mitomycin C and epirubicin, are commonly used for this therapy. BCG
treatment demonstrates strong anticancer effects. However, it is also characterized by a high frequency of adverse events. On the
other hand, although intravesical therapies using other anticancer and antibiotic agents are relatively safe, their anticancer effects
are lower than those obtained using BCG.Thus, the appropriate selection of agents for intravesical therapy is important to improve
treatment outcomes and maintain the quality of life of patients with NMIBC. In this review, we discuss the predictive value of
various histological and molecular markers for recurrence after intravesical therapy in patients with NMIBC.
1. Introduction
Urothelial cancer of the bladder is a common disease
throughout the world. Approximately two-thirds of all blad-
der cancers (BCs) are considered nonmuscle invasive bladder
cancer (NMIBC) at diagnosis [1]. Transurethral resection
(TUR) of the bladder is the standard therapy to remove
cancerous tissue from patients with NMIBC. Unfortunately,
BC frequently recurs after TUR. In fact, up to 70% of patients
with NMIBC experience local BC recurrence after receiving
the appropriate treatment. The risk of BC recurrence and
progression increases in high grade BC [2]. Intravesical
therapy is recommended to reduce the risk of recurrence
and progression in these patients. In recent years, various
therapeutic agents have been examined in preclinical and
clinical trials for use in post-TUR adjuvant intravesical
therapy [3, 4]. The most commonly used therapeutic agents
include Bacillus Calmette-Guérin (BCG) and a variety of
chemotherapeutic agents, even now.
Intravesical immunotherapy with BCG is the most effec-
tive therapy to reduce the recurrence and progression of
NMIBC and most guidelines recommend BCG therapy for
patients withNMIBC [5]. However, intravesical BCG therapy
can cause adverse effects, ranging from lower abdominal
discomfort and cystitis to bladder atrophy and sepsis. In
addition, nearly 40% of patients do not respond to intrav-
esical BCG therapy [6]. A number of patients with NMIBC
reject BCG therapy because of the high failure rates and
severe adverse effects associated with the therapy. Intravesical
therapywith chemotherapeutic or antibiotic agents is another
popular therapeutic option. Adverse effects associated with
these treatment options are rare and mild. However, some
patients in the intermediate- or high-risk groups could be
at higher risks of recurrence and progression than if they
received intravesical BCG therapy. Therefore, accurate pre-
dictions of anticancer effects associated with each intravesical
therapy are important when deciding treatment strategies in
patients with NMIBC.
In this review, we discuss the prognostic value of various
types of predictive factors for recurrence in patients with
NMIBC treated with adjuvant intravesical therapy after TUR.
Many reports have been published and well-written reviews
exist on this topic. However, many of them involve analyses
of intravesical BCG therapy. In addition, most of these
reviews were published nearly fifteen years ago. Certainly,
there are only few new and dramatic topics in this field.
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However, intravesical therapy with chemotherapeutic agents
or BCG continues to be the most commonly used and
effective therapy for patients with NMIBC. Therefore, we
made special efforts to summarize these treatments based
on reports from the past decade. There are many reports on
predictive markers in urine samples [7–9]. However, in this
review, we discuss the results obtained from tissue samples
because intravesical therapy is usually performed after TUR.
The most popular and effective agent for post-TUR
intravesical therapy is BCG. Although various types of
chemotherapeutic or antibiotic agents are used for this
therapy, most studies investigated the anticancer effects of
mitomycin C (MMC), epirubicin, and cytarabine (Ara-C).
MMC is a chemotherapeutic agent that acts by inhibiting
DNA synthesis. Epirubicin is an anthracycline antibiotic
agent that demonstrates minimal transurothelial absorption
[10]. Ara-C is an antagonist of pyrimidine metabolism that
has low incidences of local and/or general adverse effects [11].
Gemcitabine, paclitaxel, and some other newly developed
agents have also been investigated in preclinical and clinical
trials [3, 4, 12]. We pay special attention to BCG, MMC,
and epirubicin in this review because these are currently the
most popular agents and most reports regarding predictive
markers for cancer recurrence in adjuvant intravesical ther-
apy used these agents.
Numerous studies investigated how to optimize intraves-
ical therapy in patients with NMIBC by examining different
durations, timings, and regimens [13]. However, no single
best method has been determined. Intravesical therapies vary
widely in dosage, duration, and the presence or absence of
maintenance therapy even if the same agent was used. Thus,
biases and differences in the evaluation of cancer-related and
immune-related molecules in human tissues are inevitable.
In addition, there is a report that BCG efficacy in Japanese
population tended to show decreasing nonrecurrence rates
with time whereas nonrecurrence rate in western countries
increased each year [14]. Furthermore, in the Asian popula-
tion, recurrence-free survival between intravesical BCG and
intravesical MMC therapy was not significantly different [15].
Therefore, this review is limited by the lack of uniformity in
therapeutic policies, evaluationmethods, and races analyzed.
However, we believe that the information in this review
will still be useful for discussing treatment and observation
strategies in patients with NMIBC.
2. Clinical Background and
Pathological Features
Most investigators and urologists initially studied whether
certain characteristics of patients (e.g., age, gender, bodymass
index, and information on adverse effects) could predict clin-
ical outcomes and recurrence after adjuvant intravesical ther-
apy. Most of these studies suggest that these characteristics
cannot predict anticancer effects and outcomes after intrav-
esical BCG therapy [21, 30, 31]. Various pathological features
and endoscopic tumor characteristics were also analyzed for
potential prognostic capabilities in recurrence after intrav-
esical therapy. However, these factors also failed to predict
the response and time to recurrence [31]. The expression lev-
els of cancer-related molecules, immune responses, and gene
polymorphisms were also analyzed in patients as the next
potential prognostic resources. Before discussing the progno-
sis of BCG therapy in patients with NMIBC, we should note
the difference between BCG refractoriness and BCF relapse.
Recurrence-free survival and overall survival of BCG-
refractory patients are significantly worse compared to those
of BCG-relapsing patients [32]. Therefore, further detailed
studies with rigid distinction may be essential in the future.
3. Cell Proliferation
Cell proliferation is an important regulator of tumor growth,
progression, and outcome in patients with NMIBC [33, 34].
Therefore,many studies investigated the relationship between
recurrence and cell proliferation indices measured using Ki-
67-positive cells (Ki-67 labeling index; Ki-67 LI) [16, 35, 36].
However, a consensus on the value of Ki-67 for predicting
recurrence has yet to be reached. For example, patients with
a high Ki-67 LI have significantly worse recurrence-free
survival after intravesical BCG therapy than those with a
low Ki-67 LI [16, 36]. However, while a significant predictive
value was detected in a univariate analysis, it was not detected
in a multivariate analysis. Another report demonstrated that
the Ki-67 LI did not predict recurrence in intravesical BCG
therapy [19]. On the other hand, Chen et al. [18] reported
that a high Ki-67 LI (>25%) was a significant predictor
of recurrence after intravesical therapy with MMC and
epirubicin (𝑃 = 0.001) in 72 patients with pTa or pT1. Ki-67
LI was also identified as an independent prognostic indicator
in a multivariate analysis (risk ratio, 2.021; 95% confidence
interval, 1.018–4.010; 𝑃 = 0.044). When a similar analysis was
performed, high Ki-67 LI (≥20%) was a significant predictive
factor for progression-free survival in both univariate and
multivariate analyses (𝑃 = 0.006 and 𝑃 = 0.042, resp.) [17].
However, in this study, Ki-67 LI did not significantly correlate
with recurrence even in a univariate analysis [17]. No conclu-
sion can be reached about the prognostic roles of Ki-67 LI for
adjuvant MMC and epirubicin therapies because these two
studies used different protocols for intravesical therapy, chose
different cut-off values for the Ki-67 LI, and examined differ-
ent pathological features.Thus,Ki-67 LI cannot be considered
a useful predictor of recurrence after intravesical therapy. A
summary of the predictive values of Ki-67 LI for recurrence
after intravesical therapy is shown in Table 1. On the other
hand, there was a report regarding proliferating cell nuclear
antigen (PCNA) and recurrence in patients with NMIBC
treated with intravesical therapy [37]. This study showed that
rates for PCNA-positive cancer cells were 52.6% (10/19) in
recurrent and 78.9% (15/19) in nonrecurrent cases. Although
a significant difference of PCNA was not detected in recur-
rence, the number of patients was relatively small (𝑛 = 19).
4. Apoptosis and Apoptosis-Related Molecules
The induction of cell death by apoptosis is an important
anticancer effect of intravesical therapy [38]. Therefore,
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Table 1: Predictive value for recurrence in cancer-related factors and molecules.
Variable Patients Agent 𝑃 value for recurrence Year/reference
𝑁 Background Univariate Multivariate
Ki-67
92 Tis, T1G3 BCG 0.015 2009/[16]
129 T1G3 MMC 0.517 2010/[17]
72 Ta, T1 MMC/epirubicin 0.011 0.044 2012/[18]
61 T1G3 BCG 0.677 2013/[19]
P53
53 Tis, Ta, T1 BCG 0.741 2007/[20]
27 T1G3 BCG 0.92 2009/[21]
129 T1G3 MMC 0.452 2010/[17]
61 T1G3 BCG 0.794 2013/[19]
134∗ T1 HG BCG 0.830 2015/[22]
pRb
53 Tis, Ta, T1 BCG 0.580 2007/[20]
27 T1G3 BCG 0.037 2009/[21]
61 T1G3 BCG 0.951 2013/[19]
Survivin
74∗∗ Tis, Ta, T1 BCG/MMC 0.003 0.02 2007/[23]
78 Ta and T1 BCG 0.009 2012/[24]
78 Ta and T1 BCG 0.043 2012/[24]
p27 61 T1G3 BCG 0.822 2013/[19]
p63 134∗ T1 HG BCG 0.129 2015/[22]
ΔNp63 134∗ T1 HG BCG <0.001 ∗ ∗ ∗ 2015/[22]
PTEN 61 T1G3 BCG 0.306 2013/[19]
FGFR3 61 T1G3 BCG 0.355 2013/[19]
Ezrin 92 Tis, T1G3 BCG 0.041 2009/[16]
CD9 61 T1G3 BCG 0.760 2013/[19]
MVD 26 Ta, T1 BCG <0.0001 0.0011 2011/[25]
AT1R 26 Ta, T1 BCG <0.0001 0.0012 2011/[25]
VEGF 72 Ta, T1 MMC/epirubicin 0.010 0.036 2015/[26]
BCG: Bacillus Calmette-Guérin; MMC: mitomycin C; Rb: retinoblastoma; PTEN: phosphatase and tensin homolog; FGFR: fibroblast growth factor receptor;
MVD: microvessel density; AT1R: Angiotensin II Type I Receptor.
∗One hundred thirty-one (97.8%) patients were treated with adjuvant intravesical BCG therapy.
∗∗Among 74 patients, 54 (73.0%) were treated with intravesical BCG or MMC therapy.
∗∗∗Hazard ratio and 95% confidential interval were 0.383 and 0.193–0.961, respectively. 𝑃 value was not shown.
semiquantification of apoptosis may be a useful predictive
marker of recurrence after this therapy. The most popular
methods of semiquantification of apoptosis in tissue sam-
ples are currently TdT-mediated dUTP nick end labeling
(TUNEL) and the quantification of caspase-3 levels [39, 40].
These methods were also used in many studies investigat-
ing the relationships between apoptosis and carcinogenesis,
pathological features, and survival in patients with diseases,
including BC [39–41]. However, to our knowledge, only few
reports are investigating the prognostic role of the apoptotic
index measured by TUNEL and/or caspase-3 expression
after intravesical therapy in patients with NMIBC. How-
ever, several apoptosis-related molecules were investigated as
potential predictive tools and are summarized in Table 1.
4.1. TP53. Wild type p53 is a well-known regulator of cell
cycle control in normal cells and acts as a tumor suppressor
by controlling apoptotic processes under genotoxic condi-
tions. However, mutations in the p53 gene can induce cell
cycle deregulation and apoptosis in cancer cells. Nuclear
accumulation of p53 influences the malignant potential and
aggressiveness of NMIBC [32, 42]. The prognostic abilities of
p53 expression during recurrence after intravesical BCG ther-
apy were investigated, but conflicting results were obtained
[17, 19–22, 36, 37, 42–45]. However, as shown in Table 1, the
current opinion is that p53 expression has minimal value
in predicting recurrence after intravesical BCG therapy. On
the other hand, a different study found a mutation in the
gene encoding p53 that is associated with the recurrence
after intravesical BCG therapy [46]. However, this result was
achieved by a univariate analysis and the study included a
relatively small sample size (𝑛 = 26). Thus, although the
pathological significance and prognostic role of p53 have
been widely investigated, the results of these studies are
not conclusive enough to make a clinical decision. On the
other hand, in recent years, a meta-analysis demonstrated
that p53 overexpression was associated with recurrence-free
survival in patients with NMIBC treated with intravesical
BCG therapy in theAsian population (hazard ratio = 1.57, 95%
confidential interval = 1.08–2.27) [47]. This meta-analysis
has several limitations, including presence of heterogeneity,
publication bias, and a wide range of cut-off points. However,
4 Disease Markers
we support the opinion that there is value in continuing
further studies with rigid criteria and large population.
4.2. p63. The p63 protein is a member of the p53 tumor
suppressor protein family [48]. Levels of p63 expression in
NMIBC were reported to be higher than those inMIBC [49].
ΔNp63 is an isoform of p63 and it was also reported to act as a
tumor suppressor in various cancers [48, 50]. The prognostic
potential of p63 and ΔNp63 expression levels was recently
investigated in 134 patients with pT1 high-grade cancer (131
of 134 patients (97.8%) that were treated with adjuvant intrav-
esical BCG therapy) [22]. They found that ΔNp63 expression
was a significant predictive factor in both univariate andmul-
tivariate analyses, whereas p63 expression was not (Table 1).
Unfortunately, the molecular mechanisms underlying the
prognostic capabilities of ΔNp63 expression are unclear.
4.3. Survivin. Survivin is a member of the inhibitor of
apoptosis (IAP) family and it controls various pathological
activities by regulating mitosis- and apoptosis-related factors
[51]. In patients with BC, survivin expression was associated
with malignant potential and recurrence [23, 52]. Univariate
and multivariate analyses also demonstrated that survivin
expression was a significant and independent predictor of
recurrence in 74 patients with NMIBC (𝑃 = 0.003 and 𝑃 =
0.02, resp.) [23]. Among these 74 patients, however, intrav-
esical therapy was performed in only 54 (73.0%) and the
therapies used different agents (BCG or MMC). Although
further studies are necessary to conclude the prognostic
ability of survivin expression in patients with NMIBC treated
with intravesical therapy, this finding facilitates a discussion
of the different treatment strategies using intravesical therapy.
On the other hand, heterozygous genotypes (GC) of survivin
(31G>C) are significantly correlated (𝑃 = 0.0009) with the
recurrence in patients with NMIBC treated with intravesical
BCG therapy [24]. These authors also found a considerable
relationship with the homozygous genotype (CC) of survivin
(31G>C) [24].
4.4. Bcl-2 Family. The apoptotic-related molecules Bax and
Bcl-2 are strong pro- and antiapoptotic molecules, respec-
tively. Some studies suggest that these molecules contribute
to disease aggressiveness and outcome in BC. However, the
opposite results have also been found [32, 37, 53]. A higher
Bcl-2/Bax ratio (>1) is associated with early recurrence after
adjuvant intravesical chemotherapy [53]. A different report
found that Bax expression is significantly associated with the
risk of recurrence in intravesical BCG therapy, as determined
by univariate analysis (𝑃 = 0.034) [54]. This study also
showed that amodel, including pT1 stage, age, and expression
levels of Bax and Bcl-2, was the best independent and
significant predictor for recurrence after therapy. However,
we should note that the study population was relatively small
(𝑛 = 28). As the authors noted, further investigations on
a larger cohort are necessary to confidently determine the
prognostic roles of Bcl-2 and Bax for intravesical BCG
therapy in patients with NMIBC.
5. Angiogenesis and
Angiogenesis-Related Molecules
Angiogenesis is a crucial step for tumor growth and progres-
sion in almost all types of cancers, including BC [55–58].
In cancer tissues, microvessel density (MVD) is commonly
used to evaluate the angiogenic status. Several investigators
demonstrated that MVD was significantly associated with
the prognosis and recurrence in BC patients [55, 57, 58].
However, the relationship between MVD and recurrence
in patients with NMIBC treated with intravesical therapy
contradicted previous expectations. MVD was found to be
closely associated with recurrence after intravesical BCG
therapy as determined by both univariate (𝑃 < 0.0001,
Table 1) and multivariate analyses (hazard ratio, 4.35; 95%
confidence interval, 0.90–21.18; 𝑃 = 0.0011) [25]. However,
this study population was relatively small (𝑛 = 26) and the
95% confidence lower limit value was under 1.0. On the other
hand, vascular endothelial growth factor (VEGF) promotes
angiogenesis in various physiological and pathological con-
ditions. One report found that increased VEGF immunore-
activity is a worse predictor of recurrence in patients with
NMIBC treated with intravesical MMC or epirubicin therapy
[18]. As for MVD, there is little information regarding the
prognostic value of VEGF after intravesical therapy.
6. Other Cancer-Related Molecules
The retinoblastoma protein (pRB) is a well-known tumor
suppressor that acts by regulating the cell cycle. One report
indicated that pRb expression was not associated with recur-
rence after intravesical BCG and interferon-alpha therapy
(𝑃 = 0.047) [45]. On the other hand, Cormio et al. [21]
reported that altered pRB expression was significantly asso-
ciated with disease-free survival (𝑃 = 0.037) in a Kaplan-
Meier survival analysis.They also investigated the predicative
value of a combined pRb and p53 marker in these patients,
but this marker was not significantly associated with survival
(𝑃 = 0.08).
E2F4 is a member of the E2F transcription factor family.
E2F4 is involved in cell cycle regulation and the suppression
of tumor growth. This protein can bind pRB and there is a
report that E2F4 expression level is a useful predictivemarker
for the effectiveness of intravesical BCG therapy that can
predict clinical outcomes, including recurrence, progression,
and survival in patients with BC [26]. However, detailed
pathological significance and prognostic roles of E2F4 after
intravesical therapy are still largely unknown.
Ezrin expression levels are reportedly correlated with
cell survival, migration, and adhesion in several cancers
[59, 60]. Lower expression levels (<20%) of ezrin in cell
membranes are significantly associated with poor disease
outcomes in patients with T1 grade 3 disease after intravesical
BCG therapy (𝑃 = 0.041) [34]. Ezrin is a member of the
ezrin, radixin, and moesin (ERM) cytoskeleton-associated
protein family.This family is composed of ezrin, radixin, and
moesin. Currently, the prognostic roles of radixin andmoesin
in patients with NMIBC are still unknown.
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Table 2: Predictive value of immunologic microenvironment and immune cells.
Variable Patients Agents 𝑃 value for recurrence Year/reference
𝑁 Background Univariate Multivariate
CD1a 59 NMIBC BCG 0.005 2009/[27]
CD1b 59 NMIBC BCG <0.000 2009/[27]
CD1c 59 NMIBC BCG 0.03 2009/[27]
CD1e 59 NMIBC BCG 0.007 2009/[27]
MHC-1 59 NMIBC BCG <0.000 2009/[27]
MIG 59 NMIBC BCG <0.0001 2009/[27]
IP10 59 NMIBC BCG <0.0001 2009/[27]
TAM 66 NMIBC BCG 0.101 0.013 2009/[28]
CD68 41 Tis BCG 0.0002 2009/[29]
TIDC 66 NMIBC BCG 0.210 2009/[28]
CD83 30 NMIBC BCG∗ 0.045 0.039 2009/[28]
Emax 38 Tis BCG 0.01 2014/[30]
Edgn 38 Tis BCG 0.04 2014/[30]
EAI 38 Tis BCG <0.004 2014/[30]
G/T ratio 38 Tis BCG <0.001 2014/[30]
Th2 SB 38 Tis BCG <0.0001 2014/[30]
BCG: Bacillus Calmette-Guérin; MHC: major histocompatibility complex; MIG: monokine induced by 𝛾-interferon; IP10: interferon-inducible protein 10 kDa;
Emax: eosinophil infiltration; TAM: tumor-associated macrophage; TIDC: tumor infiltrating dendritic cells; Edgn: eosinophil degranulation; EAI: eosinophil
activity index; G/T: GATA-3+ lymphocytes/T-Bet+ lymphocytes; Th2 SB: Th2 signature biomarker.
∗Patients treated with more than one maintenance BCG cycle.
Mutations in fibroblast growth factor receptor- (FGFR-)
3 have been reported to play important roles in disease pro-
gression and outcome in patients with certain malignancies,
including BC [61]. However, some reports demonstrated a
lack of significant relationship between FGFR-3 mutations
and disease recurrence in BC [62, 63]. In addition, Park
et al. [19] reported that altered FGFR-3 expression was not
associated with recurrence after intravesical BCG therapy.
Phosphatase and tensin homolog (PTEN) plays impor-
tant roles in tumor suppression via the inhibition of the Akt
pathway, and its expression was reported to be decreased in
NMIBC [19, 64]. One study investigated the ability of PTEN
expression levels to predict recurrence after intravesical
therapy in T1 grade 3 tumors, but no significant association
was detected [19].
CD9, a motility-related protein, is a member of the
transmembrane-4 superfamily. The ability of CD9 to inhibit
cell motility has been reported in several cancers. However,
there is limited information regarding the pathological roles
of CD9 in BC [65]. To our knowledge, only one study has
investigated the ability of CD9 expression levels to predict
recurrence after intravesical BCG therapy, but no significant
association was found (𝑃 = 0.306) [19].
7. Immune System
The precise mechanisms of the antitumor effects of BCG in
the urinary bladder are not fully understood. Many investi-
gators believe that the response to intravesical BCG therapy
depends on a patient’s ability to generate adequate, massive,
and complex immune responses. In addition, a report shows
that BCG strains are associated with the clinical impact
in NMIBC; 5-year recurrence-free survival rates of patients
treated with BCGConnaught are better than those of patients
treated with BCG Tice (𝑃 = 0.0108) [66]. However,
other investigators showed no significant difference (𝑃 =
0.896) between BCG Tokyo and Connaught strains in the 2-
year recurrence-free survival rate [67]. On the other hand,
regarding immunization against mycobacterial antigens, the
maximal peripheral immune response is observed after 4
weekly BCG instillations in patients previously immunized.
However, patients not previously immunized required 6
weekly instillations to achieve a maximum stimulation level
[68]. Thus, anticancer effects of BCG are regulated by com-
plex immune-related mechanisms.
BCG antigen presentation leads to the regulation of vari-
ous types of immune cells (e.g., T lymphocytes, natural killer
(NK) cells, NKT cells, and macrophages) and changes in the
immunologic tumor microenvironment [30, 69]. Anticancer
and antibiotic agents can directly affect the immune system
by stimulating inflammation. Therefore, in this chapter, we
summarize the predictive value of immune-related factors
in patients with NMIBC treated with intravesical therapy
(Table 2).
7.1. Immunologic Tumor Microenvironment. Nunez-Nateras
et al. [30] investigated the relationship between the response
to intravesical BCG therapy and pretreatment of the
immunologic tumor microenvironment. They investigated
the prognostic roles of eosinophil infiltration (Emax) and
degranulation (Edgn) and the eosinophil activity index
(EAI), which is calculated as Emax + Edgn. They also
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investigated the prognostic capabilities of the GATA-3+
Th2-polarized to T-bet+ Th1-polarized lymphocyte (G/T)
ratio and the Th2 signature biomarker (Th2 SB), which is
calculated as Emax + Edgn + G/T. When these markers
were compared between patients that responded to BCG
and patients that did not respond to BCG, all markers in
responding patients were considerably higher than those
in nonresponding patients (Table 2). These authors suggest
that the evaluation of Th1 versus Th2 polarization prior to
intravesical BCG therapy is useful to predict the response to
this therapy.This information is interesting and important to
advance our understanding of treatment strategies. However,
more detailed and larger studies are necessary to make
confident conclusions, because this study had a relatively
small (𝑛 = 38) and nonrandom study population (pTis only).
Another report investigated the relationship between
the antitumor effects of intravesical BCG therapy and the
expression of antigen-presenting molecules and chemokines
[27].This report showed that patients that did not experience
recurrence had increased expression levels of antipresenting
molecules and chemokines such as CD1a, CD1b, CD1c, CD1e,
major histocompatibility complex- (MHC-) 1, monokine
induced by 𝛾-interferon (MIG), and interferon-inducible
protein 10 kDa (IP-10), after intravesical BCG therapy.
7.2. Tumor-Associated Macrophage (TAM). The immune
response has an impact on the anticancer effects of intrav-
esical BCG therapy. Therefore, many investigators have paid
special attention to the prognostic roles of immune cells in
BC. Tumor-associated macrophages (TAMs) are associated
withmalignant aggressiveness and prognosis in various types
of cancers, including BC [70, 71]. Several reports have shown
that TAM density can predict recurrence in patients with
NMIBC [29, 72, 73]. For example, in intravesical BCG ther-
apy, recurrence-free survival in patients with lower numbers
of TAMs was better than that of patients with higher TAM
counts (𝑃 = 0.0002) [29]. On the other hand, macrophages
exist in two different polarization states classified as M1
and M2. M1 macrophages demonstrate anticancer abilities
by promoting various tumor-killing mechanisms, while M2
macrophages suppress cancer-related immune responses,
stimulating tumor development and progression [72, 73].
Thus, TAMs in cancer tissues have opposite functions against
tumorigenesis and immune activity. Suriano et al. [74] inves-
tigated the predictive value of total TAMs as well as M1 and
M2 macrophage infiltration after intravesical BCG therapy.
Similarly to previous reports [72, 73], they found that total
macrophage infiltration is a significant predictor of disease-
free survival (𝑃 = 0.020). In addition, Kaplan-Meier survival
analysis showed that a low density of M1-TAM and a high
density of M2-TAM were significantly worse predictors of
disease-free survival compared to a high density of M1-TAM
and a low density of M2-TAM (𝑃 = 0.029 and 𝑃 = 0.02,
resp.) in patients with NMIBC treated with intravesical BCG
therapy [74].These results are interesting and provide critical
information about the prognostic roles of TAMs in intravesi-
cal BCG therapy. However, the independent roles of M1- and
M2-TAMs were not supported by a multivariate analysis.
7.3. Other Immune Cells and Immunity-Related Factors. One
study indicated that tumor infiltrating dendritic cell (TIDC)
levels, evaluated by CD83 expression, were not associated
with recurrence in patients treated with intravesical BCG
therapy (𝑃 = 0.210) [28]. However, when a similar analysis
was performed in patients treated with more than one main-
tenance BCG cycle, TIDC levels were positively associated
with the risk of recurrence in both univariate andmultivariate
analyses (𝑃 = 0.045 and 𝑃 = 0.039, resp.) [28].
Yutkin et al. [75] investigated the predictive value of NK
cell receptor ligands for recurrence after intravesical BCG
therapy. Interactions between NK cells and their targets
influence natural cytotoxicity receptors under pathological
conditions, including cancer. Three natural cytotoxicity
receptors (NKp30, NKp44, andNKp46) are currently known.
The authors investigated the prognostic roles of these three
receptors after intravesical BCG therapy. High expression
levels of NKp30, NKp44, and NKp46 were significantly
associated with favorable treatment responses (𝑃 = 0.0026,
𝑃 = 0.0027, and 𝑃 = 0.044, resp.) [75]. However, these results
were obtained by univariate analyses only and included a
relatively small number of patients (𝑛 = 17). However, we
believe that these findings are critical to understand the
immune mechanisms responsible for preventing recurrence
in patients with NMIBC treated with intravesical BCG
therapy.
In recent years, cytokine panel for response to intrav-
esical therapy (CyPRIT) constructed using urinary levels of
inducible cytokines was reported as a potential useful predic-
tor for the risk of recurrence during intravesical BCG therapy
[76]. Thus, we agree with the opinion that more detailed and
wider analyses of cytokines may lead to the identification
of useful predictive factors to guide modifications of the
dose and duration of BCG immunotherapy in patients with
NMIBC [77].
8. Gene Polymorphism
Polymorphisms of several genes are associated with
macrophage susceptibility to intracellular mycobacterial
growth, tuberculosis infection, and response to BCG
infection [78–80]. NRAMP1 is one of these macrophage
susceptibility-related genes. Several studies investigated
the relationships between NRAMP1 gene polymorphisms
and disease outcomes in patients with NMIBC treated
with intravesical BCG therapy [81, 82]. Of 22 tumors with
the NRAMP1 D543N G:A genotype, cancer recurred in
4 patients (18.2%). The median time to recurrence was
104.6 months. Of 47 tumors with the NRAMP1 D543N
G:G genotype, cancer recurred in 19 patients (40.4%) and
the median time to recurrence was 80.2 months. Thus,
the NRAMP1 D543N G:G genotype was associated with
a higher frequency of recurrence and a shorter time to
recurrence in patients treated with intravesical BCG therapy
(𝑃 = 0.033). This genotype is recognized as an independent
and significant predictive factor for the time to recurrence
after intravesical BCG therapy (hazard ratio, 4.57; 95%
confidence interval, 1.367–15.272; 𝑃 = 0.014). This study
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showed that the NRAMP1 (GT)n allele 3 was also associated
with decreased recurrence time in a similar multivariate
analysismodel (hazard ratio, 24.789; 95% confidence interval,
3.074–199.883; 𝑃 = 0.03).
The same study also showed that the hGPX1 CT genotype
(Pro-Lue) predicts shorter recurrence times after intravesical
BCG therapy (𝑃 = 0.03) [80]. hGPX1 is a selenium-
dependent enzyme and it participates in the detoxifica-
tion of hydrogen peroxide and oxide radicals. The codon
198 variant of hGPX1 is reportedly associated with tumor
development [83]. A significant relationship between hGPX
polymorphism and recurrence in patients with NMIBC has
also been previously reported [84]. However, this study
population included 128 patients treated with intravesical
therapy by BCG and 96 patients treated with other agents.
Although further studies are necessary to confidently assess
the predictive value of hGPX polymorphism for outcome
after intravesical BCG therapy, we believe that this gene
is a likely candidate prognosis marker. In recent years,
relationships between genetic variation in glutathione (GSH)
pathways and recurrence in patients with NMIBC treated
with BCG after TUR were analyzed. This study showed that
7265992 in GSH synthetase was the most significant (hazard
ratio = 3.43, 95% confidential interval = 2.19–13.46, 𝑃 =
0.0003) single nucleotide polymorphism in these patients
[85].
9. Concluding Remarks
Intravesical therapy is used to prevent recurrence in patients
with NMIBC. However, intravesical BCG therapy commonly
causes adverse effects. Intravesical therapy with other anti-
cancer agents or antibiotics are relatively safe, but they present
lower anticancer effects than BCG. Therefore, predictive
markers for anticancer effects, including recurrence preven-
tion, are important tools when selecting treatment strategies
for these patients. However, our current understanding of the
predictive markers for recurrence after intravesical therapy
is insufficient. Despite the fact that many studies have been
performed, few results have been verified by multivariate
analyses and there is no predictive marker in clinical use.
Treatment strategies by intravesical approaches, based on
new concepts and ideas, have been recently proposed. Fur-
ther in vivo and in vitro studies investigating prognostic
markers capable of predicting anticancer effects, clinical out-
comes, and adverse effects in new intravesical therapies are
required.
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Bacillus Calmette-Guérin,” European Urology, 2015.
[77] J. Klap, M. Schmid, and K. R. Loughlin, “Biomarkers in patients
treated with BCG: an update,” Canadian Journal of Urology, vol.
21, no. 4, pp. 7335–7343, 2014.
[78] P. Gros, E. Skamene, and A. Forget, “Genetic control of natural
resistance to Mycobacterium bovis (BCG) in mice,” Journal of
Immunology, vol. 127, no. 6, pp. 2417–2421, 1981.
[79] R. Bellamy, C. Ruwende, T. Corrah, K. P. W. J. McAdam, H.
C. Whittle, and A. V. S. Hill, “Variations in the NRAMP1 gene
and susceptibility to tuberculosis in West Africans,” The New
England Journal of Medicine, vol. 338, no. 10, pp. 640–644, 1998.
[80] P.-S. Gao, S. Fujishima, X.-Q. Mao et al., “Genetic variants
of NRAMP1 and active tuberculosis in Japanese populations,”
Clinical Genetics, vol. 58, no. 1, pp. 74–76, 2000.
[81] M. Decobert, H. LaRue, A. Bergeron et al., “Polymorphisms
of the human NRAMP1 gene are associated with response
to Bacillus Calmette-Guerin immunotherapy for superficial
bladder cancer,” Journal of Urology, vol. 175, no. 4, pp. 1506–1511,
2006.
[82] E. Chiong, A. Kesavan, R. Mahendran et al., “NRAMP1 and
hGPX1 gene polymorphism and response to Bacillus Calmette-
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